NAD boosting mediated by CD38 inhibition drives reversal of a pathological vicious cycle of intracrine activity and inflammation in eyelid meibomian gland dysfunction

The human body relies on a delicate balance of chemical signals to keep its tissues healthy and functioning. Among these signals are hormones, which are often thought of as substances traveling through the bloodstream to reach distant organs. However, some tissues produce their own hormones locally, right where they are needed, in a process known as intracrine activity. This local production is vital for maintaining the structure and function of specific organs, much like a neighborhood bakery that supplies fresh bread only to the residents on its own block rather than shipping it across the country. When this local system fails, the tissue can begin to deteriorate, often triggering a downward spiral where damage leads to more damage. This concept of a self-reinforcing negative loop, or a vicious cycle, is a common theme in aging and chronic disease, yet understanding exactly how to break these cycles remains one of the most challenging tasks in modern medicine.

A specific and common example of this breakdown occurs in the eyelids, within tiny structures called meibomian glands. These glands are responsible for producing an oily substance that coats the surface of the eye, preventing tears from evaporating too quickly. As people age, these glands often stop working properly, leading to a condition known as meibomian gland dysfunction, which is the most frequent cause of evaporative dry eye. For a long time, the exact chain of events causing this decline has been unclear. Researchers have now investigated whether the failure of these glands to produce their own local hormones plays a central role in a pathological loop that drives the disease forward. By studying aged mice, a team of scientists has uncovered a specific mechanism where inflammation and a drop in a crucial cellular fuel molecule work together to shut down the glands, creating a cycle that is difficult to stop without intervention.

The investigation began with the observation that in healthy glands, cells produce androgens, a type of hormone, locally to maintain the tissue's structure. In the aged, dysfunctional glands, this local hormone production disappears. The researchers found that this loss triggers a remodeling of the eyelid tissue, causing it to become inflamed and scarred. This inflammation, in turn, attacks the very machinery the cells need to make hormones. Specifically, the inflammation suppresses an enzyme that depends on a molecule called NAD to function. NAD is a vital energy carrier found in all living cells, essential for many chemical reactions. When the enzyme cannot work due to a lack of NAD, the gland stops making hormones entirely, which leads to even more inflammation. The result is a vicious cycle: the lack of hormones causes inflammation, and the inflammation destroys the ability to make hormones.

To understand how to break this cycle, the scientists looked for the root cause of the NAD shortage. They discovered that the aging, inflamed glands were accumulating high levels of an enzyme called CD38. This enzyme acts as a drain, breaking down NAD and depleting the cell's supply. The researchers identified this accumulation of CD38 as the key factor that shuts down the hormone-making process. To test if blocking this drain could reverse the damage, they treated aged mice with a specific compound designed to inhibit CD38. The results were striking. By stopping the enzyme from destroying NAD, the treatment restored the levels of this crucial molecule within the gland cells. With NAD levels recovered, the cells regained their ability to produce local hormones, which then suppressed the inflammatory signals.

The outcome of this intervention was a shift from a destructive loop to a beneficial one. The treatment did not just temporarily reduce symptoms; it appeared to reset the system. The glands grew back to a healthier size, and the signs of inflammation faded as the local hormone production returned. The researchers suggest that by boosting the availability of NAD, they were able to turn a pathological vicious cycle into a virtuous one, where the suppression of inflammation and the restoration of hormone activity reinforce each other. This finding offers a new perspective on how to treat age-related gland disorders, suggesting that the key to recovery lies not just in fighting inflammation directly, but in repairing the underlying metabolic engine that keeps the tissue functioning. While these results were observed in mice, they provide a clear, mechanistic explanation for how a specific molecular blockage drives a common human condition and point toward a potential strategy for reversing it.